∙ To be eligible for study participation, subjects must meet all of the following inclusion criteria.

∙ \* Criteria for the selection of the study eye

∙ If both eyes meet the criteria, the study eye will be selected according to the following criteria:

• The eye with lower (severer) best corrected visual acuity (BCVA) at baseline will be selected as the study eye.

• If both eyes have the same BCVA, the right eye will be selected as the study.

‣ Male and female ≥50 years of age at the time of written informed consent.

⁃ Treatment required, based on the judgment of the investigator, due to insufficient therapeutic efficacy despite ≥ 3 repeated doses of anti-vascular endothelial growth factor (anti-VEGF) intravitreal injection (IVT) for nAMD in the study eye, and the subject's agreement to receive the study drug instead of conventional standard therapy

⁃ \>12 weeks must have elapsed since the last dose of anti-VEGF IVT at the time of screening.

⁃ Active subfoveal or parafoveal choroidal neovascularization (CNV)\* confirmed by fundus fluorescein angiography (FFA), spectral domain-optical coherence tomography (SD-OCT), and IndoCyanine Green (ICG) angiography.

‣ \*Active CNV (confirmed by the central reading center) is defined as the presence of subretinal fluid (SRF) or intraretinal fluid (IRF) in consequence of vascular leakage.

⁃ The size of the entire lesion in the study eye (including blood, atrophy, fibrosis, and neovascularization) must be ≤ 9-disc areas, and the area of CNV in the study eye must account for ≥ 50% of the total area of the lesion, as confirmed by FFA and ICG angiography.

⁃ BCVA measured in the study eye must be between ≥ 23 letters and ≤ 78 letters based on the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart (Snellen visual acuity 20/25 - 20/320).

⁃ Voluntary written informed consent to study participation.